Show simple item record

dc.contributor.authorKatsinas, Nicolaos 
dc.contributor.authorEnriquez De Salamanca Aladro, Amalia 
dc.contributor.authorBento da Silva, Andreia
dc.contributor.authorBronze, Maria Rosario
dc.contributor.authorRodríguez Rojo, Soraya
dc.date.accessioned2022-09-23T10:27:17Z
dc.date.available2022-09-23T10:27:17Z
dc.date.issued2021
dc.identifier.citationMolecules, 2021, Vol. 26, Nº. 19, 23 pp.es
dc.identifier.issn1420-3049es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/55611
dc.descriptionProducción Científicaes
dc.description.abstractNowadays, increasing interest in olive pomace (OP) valorization aims to improve olive’s industry sustainability. Interestingly, several studies propose a high-value application for OP extracts containing its main phenolic compounds, hydroxytyrosol and oleuropein, as therapy for ocular surface diseases. In this work, the stability and accessibility of OP total phenolic and flavonoid content, main representative compounds, and antioxidant activity were assessed under different pretreatment conditions. Among them, lyophilization and supercritical CO2 extraction were found to increase significantly most responses measured in the produced extracts. Two selected extracts (CONV and OPT3) were obtained by different techniques (conventional and pressurized liquid extraction); Their aqueous solutions were characterized by HPLC-DAD-MS/MS. Additionally, their safety and stability were evaluated according to EMA requirements towards their approval as ophthalmic products: their genotoxic effect on ocular surface cells and their 6-months storage stability at 4 different temperature/moisture conditions (CPMP/ICH/2736/99), together with pure hydroxytyrosol and oleuropein solutions. The concentration of hydroxytyrosol and oleuropein in pure or extract solutions was tracked, and possible degradation products were putatively identified by HPLC-DAD-MS/MS. Hydroxytyrosol and oleuropein had different stability as standard or extract solutions, with oleuropein also showing different degradation profile. All compounds/extracts were safe for ophthalmic use at the concentrations tested.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherMDPIes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectOjo - Enfermedades y defectos - Tratamientoes
dc.subjectAceite de olivaes
dc.subjectAceite de oliva - Análisises
dc.subject.classificationOlive pomacees
dc.subject.classificationPhenolic extractses
dc.titleOlive pomace phenolic compounds stability and safety evaluation: from raw material to future ophthalmic applicationses
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2021 The Authorses
dc.identifier.doi10.3390/molecules26196002es
dc.relation.publisherversionhttps://www.mdpi.com/1420-3049/26/19/6002es
dc.identifier.publicationfirstpage1es
dc.identifier.publicationissue19es
dc.identifier.publicationlastpage23es
dc.identifier.publicationtitleMoleculeses
dc.identifier.publicationvolume26es
dc.peerreviewedSIes
dc.description.projectEuropean Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Initial Training Network (ITN) “IT-DED3” (H2020-MSCA-ITN-2017) grant agreement No. 765608es
dc.description.projectFundação para a Ciência e Tecnologia (FCT) and Portugal 2020 to the Portuguese Mass Spectrometry Network (Rede Nacional de Espectrometria de Massa RNEM; LISBOA 01 0145 FEDER 402 022125)es
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/765608
dc.identifier.essn1420-3049es
dc.rightsAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones
dc.subject.unesco3201.09 Oftalmologíaes


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record